These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28370222)

  • 1. Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.
    Mendizabal M; Haddad L; Gallardo PE; Ferrada A; Soza AA; Adrover R; Aravena E; Roblero JP; Prieto J; Vujacich C; Romero G; Muñoz A; Anders M; Hernández N; Coccozella D; Gruz F; Reggiardo MV; Ruf AE; Varón A; Cartier M; Pérez Ravier R; Ridruejo E; Peralta M; Poncino D; Vorobioff J; Aballay Soteras G; Silva MO
    J Med Virol; 2017 Sep; 89(9):1590-1596. PubMed ID: 28370222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.
    Muñoz-Gómez R; Rincón D; Ahumada A; Hernández E; Devesa MJ; Izquierdo S; Ortiz M; Hernández-Albujar A; Fernández-Rodríguez C; Calvo M; González R; Lozano M; Castellano G; Fernández-Vázquez I
    J Viral Hepat; 2017 Jun; 24(6):464-471. PubMed ID: 27976490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
    Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
    Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
    Dore GJ; Conway B; Luo Y; Janczewska E; Knysz B; Liu Y; Streinu-Cercel A; Caruntu FA; Curescu M; Skoien R; Ghesquiere W; Mazur W; Soza A; Fuster F; Greenbloom S; Motoc A; Arama V; Shaw D; Tornai I; Sasadeusz J; Dalgard O; Sullivan D; Liu X; Kapoor M; Campbell A; Podsadecki T
    J Hepatol; 2016 Jan; 64(1):19-28. PubMed ID: 26321288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
    Poordad F; Nelson DR; Feld JJ; Fried MW; Wedemeyer H; Larsen L; Cohen DE; Cohen E; Mobashery N; Tatsch F; Foster GR
    J Hepatol; 2017 Oct; 67(4):700-707. PubMed ID: 28645740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.
    Fuchs M; Monto A; Bräu N; Charafeddine M; Schmidt W; Kozal M; Naggie S; Cheung R; Schnell G; Yu Y; Richards K; Mullally V; Cohen DE; Toro D
    J Med Virol; 2020 Dec; 92(12):3459-3464. PubMed ID: 31829433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients.
    Loo N; Lawitz E; Alkhouri N; Wells J; Landaverde C; Coste A; Salcido R; Scott M; Poordad F
    World J Gastroenterol; 2019 May; 25(18):2229-2239. PubMed ID: 31143073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
    Flisiak R; Janczewska E; Wawrzynowicz-Syczewska M; Jaroszewicz J; Zarębska-Michaluk D; Nazzal K; Bolewska B; Bialkowska J; Berak H; Fleischer-Stępniewska K; Tomasiewicz K; Karwowska K; Rostkowska K; Piekarska A; Tronina O; Madej G; Garlicki A; Lucejko M; Pisula A; Karpińska E; Kryczka W; Wiercińska-Drapało A; Mozer-Lisewska I; Jabłkowski M; Horban A; Knysz B; Tudrujek M; Halota W; Simon K
    Aliment Pharmacol Ther; 2016 Nov; 44(9):946-956. PubMed ID: 27611776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A real-world study of paritaprevir/ritonavir-ombitasvir combined with dasabuvir in the treatment of genotype 1b chronic hepatitis C].
    Liu JP; Cheng YQ; Zhang JM; Jin HM; Ning HB; Li K; Ma MY; Wu YN; Peng Z; Yin H; Liu CP; Shang J
    Zhonghua Gan Zang Bing Za Zhi; 2018 Dec; 26(12):927-932. PubMed ID: 30669786
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.
    Aygen B; Demirtürk N; Yıldız O; Çelen MK; Çelik İ; Barut Ş; Ural O; Batırel A; Mıstık R; Şimşek F; Asan A; Ersöz G; Türker N; Bilgin H; Kınıklı S; Karakeçili F; Zararsız G; Turkish Society Of Clinical Microbiology And Infectious Diseases TSGFVHOT
    Turk J Gastroenterol; 2020 Apr; 31(4):305-317. PubMed ID: 32412901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
    Chamorro-de-Vega E; Gimenez-Manzorro A; Rodriguez-Gonzalez CG; Escudero-Vilaplana V; De Lorenzo-Pinto A; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo Saez M;
    Expert Opin Drug Saf; 2018 Mar; 17(3):235-241. PubMed ID: 29325476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
    Ascione A; De Luca M; Melazzini M; Montilla S; Trotta MP; Petta S; Puoti M; Sangiovanni V; Messina V; Bruno S; Izzi A; Villa E; Aghemo A; Zignego AL; Orlandini A; Fontanella L; Gasbarrini A; Marzioni M; Giannini EG; Craxì A;
    Infection; 2018 Oct; 46(5):607-615. PubMed ID: 29808463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
    Manuel Sousa J; Vergara M; Pulido F; Sánchez Antolín G; Hijona L; Carnicer F; Rincón D; Salmerón J; Mateos-Muñoz B; Jou A; Polo-Lorduy B; Rubín Á; Escarda A; Aguilar P; Aldámiz-Echevarría T; García-Buey L; Carrión JA; Hernández-Guerra M; Chimeno-Hernández S; Espinosa N; Morillas RM; Andrade RJ; Delgado M; Gallego A; Magaz M; Moreno-Planas JM; Estébanez Á; Rico M; Menéndez F; Sampedro B; Morano L; Izquierdo S; Zozaya JM; Rodríguez M; Morán-Sánchez S; Lorente S; Martín-Granizo I; Von-Wichmann MÁ; Delgado M; Manzanares A
    PLoS One; 2019; 14(11):e0225061. PubMed ID: 31714950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.
    Perelló C; Carrión JA; Ruiz-Antorán B; Crespo J; Turnes J; Llaneras J; Lens S; Delgado M; García-Samaniego J; García-Paredes F; Fernández I; Morillas RM; Rincón D; Porres JC; Prieto M; Lázaro Ríos M; Fernández-Rodríguez C; Hermo JA; Rodríguez M; Herrero JI; Ruiz P; Fernández JR; Macías M; Pascasio JM; Moreno JM; Serra MÁ; Arenas J; Real Y; Jorquera F; Calleja JL;
    J Viral Hepat; 2017 Mar; 24(3):226-237. PubMed ID: 27976491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
    Sanai FM; Alghamdi AS; Afghani AA; Alswat K; AlZanbagi A; Alghamdi MN; AlMousa A; Aseeri M; Assiri AM; Babatin MA
    Liver Int; 2018 Aug; 38(8):1395-1401. PubMed ID: 29288514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.
    Ahmed H; Abushouk AI; Menshawy A; Mohamed A; Negida A; Loutfy SA; Abdel-Daim MM
    Clin Drug Investig; 2017 Nov; 37(11):1009-1023. PubMed ID: 28871475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort.
    Puigvehí M; De Cuenca B; Viu A; Diago M; Turnes J; Gea F; Pascasio JM; Lens S; Cabezas J; Badia E; Olveira A; Morillas RM; Torras X; Montoliu S; Cordero P; Castro JL; Salmerón J; Molina E; Sánchez-Ruano JJ; Moreno J; Antón MD; Moreno JM; De la Vega J; Calleja JL; Carrión JA
    Liver Int; 2019 Jan; 39(1):90-97. PubMed ID: 30160363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.
    Chamorro-de-Vega E; Gimenez-Manzorro A; Rodriguez-Gonzalez CG; Escudero-Vilaplana V; Collado Borrell R; Ibañez-Garcia S; Lallana Sainz E; Lobato Matilla E; Lorenzo-Pinto A; Manrique-Rodriguez S; Fernandez-Llamazares CM; Marzal-Alfaro M; Ribed A; Romero Jimenez RM; Sarobe Gonzalez C; Herranz A; Sanjurjo M
    Ann Pharmacother; 2016 Nov; 50(11):901-908. PubMed ID: 27422641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
    Abdel-Moneim A; Aboud A; Abdel-Gabbar M; Zanaty M; Ramadan M
    Dig Dis Sci; 2018 May; 63(5):1341-1347. PubMed ID: 29546644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.